Retractable Technologies Inc (NYSE: RVP) is a medical device manufacturing company that designs and produces safety syringes, retractable needles, and related products for healthcare settings. Revenue is transactional, generated through direct sales of disposable medical devices to distributors and healthcare customers domestically and internationally. The company manufactures products both at its U.S. facility and through a contract arrangement with a Chinese supplier under a long-term fixed-price contract, though it is transitioning toward greater domestic production. Syringes comprised 65.1% of sales in FY2025, EasyPoint retractable needles accounted for 31.2% of sales, and other products including IV safety catheters and blood collection items made up the remainder. International sales represented 15.8% of revenues in FY2025. As of December 31, 2025, total stockholders' equity was $74.4 million against a market capitalization of $23.1 million. The company has been manufacturing and marketing products since 1997 and employed 201 people as of March 9, 2026.

Revenue model

Transactional sales of disposable safety medical devices, primarily syringes and retractable needles, sold through distributors. Customer rebates are a material contractual allowance against revenue. Syringe sales carry higher average selling prices and gross profit margins than other product lines per FY2025 disclosures.

Products and services

VanishPoint and related safety syringes (65.1% of FY2025 sales), EasyPoint retractable needles (31.2% of FY2025 sales), IV safety catheters, and blood collection products. EasyPoint needles feature automated retraction while the needle remains in the patient, differentiating them from manually activated competing safety needles.

Customers and end markets

Healthcare distributors and end-use healthcare providers including hospitals and clinics. Domestic customers retained excess syringe inventory purchased for vaccination purposes, depressing demand as of FY2025. The U.S. government has been a material customer under a Technology Investment Agreement (TIA) tied to pandemic-era capacity expansion, though this is described as non-indicative of ongoing operations.

Value-chain role

Vertically integrated manufacturer and marketer of safety medical devices. Produces domestically in Texas and sources finished goods from a Chinese contract manufacturer under a fixed-price contract. The company sells through distribution channels and manages customer rebate programs directly.

Geographic exposure

Primarily domestic U.S. sales. International sales were 15.8% of revenues in FY2025. Some international orders are shipped directly from China to the customer. The company faces tariff risk on imported finished goods and potential reciprocal tariffs on international sales.

Source: SEC 10-K, filed 2026-03-27

Industry: Surgical & Medical Instruments & Apparatus Peers: Xtant Medical Holdings Inc SURGALIGN HOLDINGS, INC. Axe Compute Inc Sanara Medtech Inc United Health Products Inc OraSure Technologies Inc VolitionRX Ltd PROJECT SAGE OLDCO, INC. TELA Bio Inc